Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

14 December 2013

Drug majors Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (LSE: AZN) have reportedly decided to stop marketing their diabetes drug Forxiga (dapagliflozin) in Germany, having failed to reach agreement on pricing of the drug with the country’s regulatory authorities.

Anglo-Swedish AstraZeneca has so far failed to respond to a request from The Pharma Letter for comment. However, according to a report from Bloomberg, the companies issued a joint statement noting: “The product will continue to be available by prescription until the current supply in the market is exhausted. AstraZeneca and Bristol-Myers Squibb will reassess the decision to stop supplying Forxiga in Germany once the arbitration process is completed.”

IQWiG found no “added benefit” for Forxiga

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK